Tag
Nand Kishor Ray
2 articles
Johnson Pharmacare SEBI Reg 32 Non-Applicability FY2026
Johnson Pharmacare submits regulatory undertaking to BSE regarding SEBI LODR compliance.
Company certifies Regulation 32 is not applicable for FY2026 ending March 31.
No share issuances via public, ri
Johnson Pharmacare FY26 Net Loss ₹5573 Lakhs
Johnson Pharmacare reported audited FY26 results with a massive standalone net loss of ₹5573.39 lakhs, approved by the board on May 27, 2026.
The company's financial position deteriorated severely, wi